0000791908--12-312023Q1false0.539060.523440.539060.523440.020000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-062021-10-060000791908xoma:AronoraIncMemberxoma:SiliconValleyBankMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:ChiefInvestmentOfficerMemberxoma:StockOptionInducementAwardsMember2023-01-032023-01-030000791908xoma:ChiefInvestmentOfficerMember2023-01-032023-01-030000791908xoma:ChiefExecutiveOfficerInterimMember2023-01-032023-01-030000791908us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023-01-012023-03-310000791908xoma:AptevoMember2023-01-012023-03-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2017-12-062017-12-060000791908xoma:RezoluteIncMemberxoma:LicenseAgreementNonRz358ProductsMember2017-12-062017-12-060000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember2006-11-012006-11-010000791908srt:ScenarioForecastMemberxoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember2023-04-012023-10-310000791908xoma:AffitechResearchAsMember2023-01-012023-03-310000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:NovartisPharmaAGMemberxoma:IL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:SecondRoyaltyInterestAcquisitionAgreementMember2016-12-212016-12-210000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember2016-12-212016-12-210000791908xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember2022-11-012022-11-010000791908srt:MaximumMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052021-08-050000791908srt:MaximumMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182018-12-180000791908xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember2023-01-012023-03-310000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-03-222021-03-220000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2020-11-022020-11-020000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2019-09-262019-09-260000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-09-012019-09-300000791908xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember2022-11-010000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000791908us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000791908xoma:AgenusIncMemberxoma:IncyteImmunoOncologyAssetsMemberxoma:RoyaltyPurchaseAgreementMember2018-09-202018-09-200000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2019-02-252019-02-2500007919082021-06-012021-06-010000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2022-05-012022-05-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2022-07-012022-07-310000791908xoma:AffitechResearchAsMembersrt:EuropeMemberxoma:CommercialPaymentPurchaseAgreementMember2022-01-012022-12-310000791908xoma:AffitechResearchAsMembercountry:USxoma:CommercialPaymentPurchaseAgreementMember2022-01-012022-12-310000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2020-11-012020-11-300000791908dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052021-08-050000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2021-03-102021-03-100000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182018-12-180000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2022-01-310000791908xoma:ObsevaIntellectualPropertyRightsMemberxoma:LicenseAgreementMember2022-11-210000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2019-08-012019-08-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-060000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-07-140000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2020-11-020000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2018-09-200000791908xoma:RezoluteIncMemberxoma:LicenseAgreementAndCommonStockPurchaseAgreementMember2017-12-062020-12-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:FirstRoyaltyInterestAcquisitionAgreementMember2016-12-210000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2021-07-142021-07-140000791908xoma:RezoluteIncMemberxoma:LicenseAgreementRz358Member2017-12-060000791908xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember2017-08-240000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-300000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:MezagitamabMemberxoma:CollaborationAgreementMember2006-11-010000791908xoma:OrganonMemberxoma:LicenseAgreementMember2022-11-210000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:OtherAntibodiesMemberxoma:CollaborationAgreementMember2009-02-012009-02-280000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-072019-04-070000791908xoma:BioasisTechnologiesIncMembersrt:MaximumMemberxoma:RoyaltyPurchaseAgreementMember2019-02-250000791908xoma:AronoraKurosAffitechObsevaAndMerckKgaaMember2023-03-310000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-03-290000791908xoma:AffitechResearchAsMemberxoma:ContingentConsiderationRegulatoryMilestonesMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-060000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2019-02-250000791908us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000791908us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000791908xoma:ChiefExecutiveOfficerRetiredMember2022-01-012022-12-310000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-03-292023-03-290000791908xoma:AffitechResearchAsMemberxoma:FaricimabProductMemberxoma:CommercialPaymentPurchaseAgreementMember2021-10-062021-10-060000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2023-01-012023-03-310000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-01-012023-03-310000791908xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember2023-03-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2023-02-012023-02-280000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2022-08-012022-08-310000791908xoma:AgenusIncMemberxoma:MerckImmunoOncologyProductMemberxoma:RoyaltyPurchaseAgreementMember2020-11-012020-11-3000007919082023-03-100000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2017-12-062017-12-060000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-09-302015-09-300000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2021-03-220000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2019-09-260000791908xoma:AronoraIncMemberxoma:NonBayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:AronoraIncMemberxoma:BayerProductsMemberxoma:RoyaltyPurchaseAgreementMember2019-04-070000791908xoma:ChiefExecutiveOfficerRetiredMember2023-03-310000791908xoma:ChiefExecutiveOfficerRetiredMember2022-12-310000791908us-gaap:CommonStockMember2023-01-012023-03-310000791908us-gaap:CommonStockMember2022-01-012022-03-310000791908dei:AdrMemberxoma:AtMarketIssuanceSalesAgreement2021Member2021-08-052023-03-310000791908us-gaap:CommonStockMemberxoma:TwoThousandEighteenAtMarketAgreementMember2018-12-182023-03-310000791908xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember2017-08-242017-08-240000791908xoma:RezoluteIncMember2020-10-012020-10-310000791908us-gaap:RetainedEarningsMember2023-03-310000791908us-gaap:AdditionalPaidInCapitalMember2023-03-310000791908us-gaap:RetainedEarningsMember2022-12-310000791908us-gaap:AdditionalPaidInCapitalMember2022-12-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2022-03-310000791908us-gaap:RetainedEarningsMember2022-03-310000791908us-gaap:AdditionalPaidInCapitalMember2022-03-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2021-12-310000791908us-gaap:RetainedEarningsMember2021-12-310000791908us-gaap:AdditionalPaidInCapitalMember2021-12-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2023-03-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2023-03-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-03-310000791908us-gaap:CommonStockMember2023-03-310000791908us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2022-12-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2022-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-12-310000791908us-gaap:CommonStockMember2022-12-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2022-03-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-03-310000791908us-gaap:CommonStockMember2022-03-310000791908us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-12-310000791908us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-12-310000791908us-gaap:CommonStockMember2021-12-3100007919082023-01-030000791908xoma:NovartisPharmaAGMemberus-gaap:CommonStockMemberxoma:XOMA052LicenseAgreementMember2017-08-2400007919082022-01-012022-12-310000791908xoma:ChiefInvestmentOfficerMemberxoma:StockOptionInducementAwardOneMember2023-01-032023-01-030000791908xoma:ChiefExecutiveOfficerInterimMemberxoma:StockOptionInducementAwardTwoMember2023-01-032023-01-030000791908xoma:ChiefExecutiveOfficerInterimMemberxoma:StockOptionInducementAwardOneMember2023-01-032023-01-030000791908xoma:StockOptionInducementAwardTwoMember2022-01-012022-03-310000791908xoma:StockOptionInducementAwardOneMember2022-01-012022-03-310000791908us-gaap:EmployeeStockOptionMemberxoma:StockOptionInducementAwardTwoMember2023-01-012023-03-310000791908us-gaap:EmployeeStockOptionMemberxoma:StockOptionInducementAwardOneMember2023-01-012023-03-310000791908us-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2022-01-012022-03-310000791908xoma:ChiefInvestmentOfficerMemberxoma:StockOptionInducementAwardTwoMember2023-01-032023-01-030000791908xoma:EmployeeMemberus-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023-01-012023-03-310000791908srt:DirectorMemberus-gaap:EmployeeStockOptionMemberxoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023-01-012023-03-310000791908xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023-01-012023-03-310000791908xoma:StockOptionInducementAwardTwoMember2023-01-012023-03-310000791908xoma:StockOptionInducementAwardOneMember2023-01-012023-03-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2023-01-012023-03-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2022-01-012022-03-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2023-01-012023-03-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2023-01-012023-03-310000791908xoma:ObsevaIntellectualPropertyRightsMemberxoma:LicenseAgreementMember2023-01-012023-03-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2023-01-012023-03-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2023-01-012023-03-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2023-01-012023-03-310000791908xoma:AffimedMemberxoma:LicenseAgreementMember2023-01-012023-03-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2022-01-012022-03-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2022-01-012022-03-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2022-01-012022-03-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2022-01-012022-03-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2022-01-012022-03-310000791908xoma:AffimedMemberxoma:LicenseAgreementMember2022-01-012022-03-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2022-01-012022-01-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2021-12-012021-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2021-10-012021-10-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2021-05-012021-05-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2020-11-012020-11-300000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2020-10-012020-10-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2019-01-012019-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2017-01-012017-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2015-01-012015-12-310000791908xoma:NovartisPharmaAGMemberxoma:XOMA052LicenseAgreementMember2017-08-242017-08-240000791908us-gaap:SeriesBPreferredStockMember2023-03-310000791908us-gaap:SeriesAPreferredStockMember2023-03-310000791908us-gaap:ConvertiblePreferredStockMember2023-03-310000791908us-gaap:SeriesBPreferredStockMember2022-12-310000791908us-gaap:SeriesAPreferredStockMember2022-12-310000791908us-gaap:ConvertiblePreferredStockMember2022-12-310000791908us-gaap:SeriesBPreferredStockMember2023-02-222023-02-220000791908us-gaap:SeriesAPreferredStockMember2023-02-222023-02-220000791908us-gaap:SeriesBPreferredStockMember2022-10-262022-10-260000791908us-gaap:SeriesAPreferredStockMember2022-10-262022-10-260000791908us-gaap:SeriesBPreferredStockMember2023-04-172023-04-170000791908us-gaap:SeriesAPreferredStockMember2023-04-172023-04-170000791908us-gaap:SeriesBPreferredStockMember2023-01-172023-01-170000791908us-gaap:SeriesAPreferredStockMember2023-01-172023-01-170000791908us-gaap:SeriesBPreferredStockMember2022-01-012022-03-310000791908us-gaap:SeriesAPreferredStockMember2022-01-012022-03-310000791908us-gaap:SeriesBPreferredStockMember2023-01-012023-03-310000791908us-gaap:SeriesBPreferredStockMember2022-01-012022-12-310000791908us-gaap:SeriesAPreferredStockMember2022-01-012022-12-310000791908us-gaap:RetainedEarningsMember2023-01-012023-03-310000791908us-gaap:RetainedEarningsMember2022-01-012022-03-310000791908xoma:BiotechnologyValueFundLPMemberxoma:XomaCorporationMemberus-gaap:CommonStockMember2023-03-3100007919082023-01-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2016-12-212016-12-210000791908xoma:ObsevaIntellectualPropertyRightsMember2022-01-012022-12-310000791908us-gaap:IntellectualPropertyMember2023-03-310000791908us-gaap:IntellectualPropertyMember2022-12-310000791908xoma:RezoluteIncMember2023-01-012023-03-310000791908xoma:RezoluteIncMember2022-01-012022-03-310000791908xoma:RezoluteIncMember2023-03-310000791908xoma:RezoluteIncMember2022-12-310000791908us-gaap:MeasurementInputSharePriceMember2023-03-310000791908us-gaap:MeasurementInputSharePriceMember2022-12-310000791908us-gaap:EmployeeStockOptionMember2023-03-310000791908us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2023-03-310000791908xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMemberxoma:RoyaltyInterestAcquisitionAgreementsMember2022-12-310000791908xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember2023-01-012023-03-310000791908xoma:NovartisNoteMember2020-10-012020-10-310000791908xoma:ObsevaIntellectualPropertyRightsMemberxoma:LicenseAgreementMember2023-03-310000791908xoma:ObsevaIntellectualPropertyRightsMemberxoma:LicenseAgreementMember2022-12-310000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2023-03-310000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2023-03-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2023-03-310000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2023-03-310000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2023-03-310000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2023-03-310000791908xoma:AptevoMemberxoma:CommercialPaymentPurchaseAgreementMember2023-03-310000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2023-03-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2023-03-310000791908xoma:ViractaTherapeuticsInc.Memberxoma:RoyaltyPurchaseAgreementMember2022-12-310000791908xoma:PalobiofarmaSLMemberxoma:RoyaltyPurchaseAgreementMember2022-12-310000791908xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMemberxoma:RoyaltyPurchaseAgreementMember2022-12-310000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementTwoMember2022-12-310000791908xoma:BioasisTechnologiesIncMemberxoma:RoyaltyPurchaseAgreementMember2022-12-310000791908xoma:AronoraIncMemberxoma:RoyaltyPurchaseAgreementMember2022-12-310000791908xoma:AgenusIncMemberxoma:RoyaltyPurchaseAgreementMember2022-12-310000791908xoma:AffitechResearchAsMemberxoma:CommercialPaymentPurchaseAgreementMember2022-12-310000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000791908xoma:Partner3Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000791908xoma:Partner2Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000791908xoma:Partner1Memberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310000791908xoma:TenYearWarrantsIssuedThirdRangeMember2023-03-310000791908xoma:CommonStockWarrantExercisePrice14.71Member2023-03-310000791908xoma:TenYearWarrantsIssuedThirdRangeMember2022-12-310000791908xoma:CommonStockWarrantExercisePrice14.71Member2022-12-3100007919082022-03-3100007919082021-12-310000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000791908us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000791908us-gaap:FairValueMeasurementsRecurringMember2023-03-310000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000791908us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000791908us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000791908us-gaap:FairValueMeasurementsRecurringMember2022-12-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2023-03-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2023-03-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2023-03-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2023-03-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2023-03-310000791908xoma:AffimedMemberxoma:LicenseAgreementMember2023-03-310000791908xoma:TakedaPharmaceuticalCompanyLimitedMemberxoma:CollaborationAgreementMember2022-12-310000791908xoma:RezoluteIncMemberxoma:LicenseAgreementMember2022-12-310000791908xoma:NovartisPharmaAGMemberxoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2022-12-310000791908xoma:NovartisInternationalPharmaceuticalLtdMemberxoma:LicenseAgreementMember2022-12-310000791908xoma:JanssenBiotechInc.Memberxoma:LicenseAgreementMember2022-12-310000791908xoma:AffimedMemberxoma:LicenseAgreementMember2022-12-310000791908us-gaap:WarrantMember2023-01-012023-03-310000791908us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000791908us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310000791908us-gaap:WarrantMember2022-01-012022-03-310000791908us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000791908us-gaap:ConvertiblePreferredStockMember2022-01-012022-03-310000791908xoma:ObsevaIntellectualPropertyRightsMember2023-01-012023-03-310000791908us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310000791908us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310000791908us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000791908us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100007919082022-01-012022-03-310000791908xoma:ObsevaIntellectualPropertyRightsMember2022-11-212022-11-2100007919082022-11-212022-11-2100007919082023-03-3100007919082022-12-310000791908us-gaap:SeriesAPreferredStockMember2023-01-012023-03-310000791908us-gaap:CommonStockMember2023-01-012023-03-310000791908dei:AdrMember2023-01-012023-03-3100007919082023-05-0400007919082023-01-012023-03-31xoma:customerxoma:facilityxoma:installmentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purexoma:itemxoma:productiso4217:EURxoma:periodxoma:agreement

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to__________

Commission File No. 001-39801

XOMA Corporation

(Exact name of registrant as specified in its charter)

Delaware

   

52-2154066

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

 

 

2200 Powell Street, Suite 310

Emeryville, California

94608

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (510) 204-7200

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading symbol(s):

Name of each exchange on which registered:

Common Stock, $0.0075 par value

XOMA

The Nasdaq Global Market

8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05

XOMAP

The Nasdaq Global Market

Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)

XOMAO

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of May 4, 2023, the registrant had 11,461,068 shares of common stock, $0.0075 par value per share, outstanding.

Table of Contents

XOMA CORPORATION

FORM 10-Q

TABLE OF CONTENTS

    

    

Page

Glossary of Terms and Abbreviations

1

PART I

FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements

4

Condensed Consolidated Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022

4

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2023 and 2022 (unaudited)

5

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2023 and 2022 (unaudited)

6

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022 (unaudited)

7

Notes to Condensed Consolidated Financial Statements (unaudited)

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

36

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

42

Item 4.

Controls and Procedures

42

PART II

OTHER INFORMATION

42

Item 1.

Legal Proceedings

42

Item 1A.

Risk Factors

42

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

73

Item 3.

Defaults Upon Senior Securities

73

Item 4.

Mine Safety Disclosure

73

Item 5.

Other Information

73

Item 6.

Exhibits

74

Signatures

76

Table of Contents

GLOSSARY OF TERMS AND ABBREVIATIONS

Abbreviations

    

Definition

2010 Plan

the Company's 2010 Long Term Incentive and Stock Award Plan, as amended

2018 Common Stock ATM Agreement

At The Market Issuance Sales Agreement with HCW dated December 18, 2018

2021 Series B Preferred Stock ATM Agreement

At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021

‘40 Act

Investment Company Act of 1940

ACA

The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010

Affimed

Affimed N.V.

Affitech

Affitech Research AS

Affitech CPPA

the Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021

Agenus

Agenus, Inc. and certain affiliates

Agenus RPA

the Company's Royalty Purchase Agreement with Agenus dated September 20, 2018

Anti-TGFβ Antibody License Agreement

the Company's License Agreement with Novartis dated September 30, 2015

April 2022 Letter Agreement

the Letter Agreement to Officer Employment Agreement dated August 7, 2017, between XOMA Corporation and Thomas Burns dated April 1, 2022

Aptevo

Aptevo Therapeutics Inc.

Aptevo CPPA

the Company’s Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as “Aptevo Commercial Payment Purchase Agreement” or “Aptevo CPPA”

Aronora

Aronora, Inc.

Aronora RPA

the Company's Royalty Purchase Agreement with Aronora dated April 7, 2019

AstraZeneca

AstraZeneca plc

ASC

Accounting Standards Codification

ASC 326

ASC Topic 326, Financial Instruments – Credit Losses

ASC 450

ASC Topic 450, Contingencies

ASC 606

ASC Topic 606, Revenue from Contracts with Customers

ASC 730

ASC Topic 730, Research and Development

ASC 805

ASC Topic 805, Business Combinations

ASC 815

ASC Topic 815, Derivatives and Hedging

ASC 842

ASC Topic 842, Leases

ASU

Accounting Standards Update

Bayer

Bayer Pharma AG

Bioasis

Bioasis Technologies, Inc. and certain affiliates

Bioasis RPA

the Company's Royalty Purchase Agreement with Bioasis dated February 25, 2019

BLA

Biologic License Application

Black-Scholes Model

Black-Scholes Option Pricing Model

B. Riley

B. Riley Securities, Inc.

BVF

Biotechnology Value Fund, L.P.

CCPA

California Consumer Privacy Act of 2018, collectively the Act and its regulations

CARES

Coronavirus Aid, Relief, and Economic Security

cGMP

current Good Manufacturing Practice

Chiesi

Chiesi Farmaceutici S.p.A.

Chiron

Chiron Corporation

Chiron Collaboration Agreement

the Company's Collaboration Agreement with Chiron dated February 27, 2004, as amended in May 2005, July 2008 and September 2015

Company

XOMA Corporation, including subsidiaries

1

Table of Contents

CPPA

Commercial Payment Purchase Agreement

CPRA

California Privacy Rights Act

EC

European Commission

EMA

European Medicines Agency

ESPP

2015 Employee Stock Purchase Plan, as amended

EU

European Union

FCPA

U.S. Foreign Corrupt Practices Act of 1977, as amended

FDA

U.S. Food and Drug Administration

FDIC

Federal Deposit Insurance Corporation

GAAP

Generally accepted accounting principles

G&A

General and administrative

GDPR

General Data Protection Regulation

Gevokizumab License Agreement

the Company's License Agreement with Novartis dated August 24, 2017

HCRP

Healthcare Royalty Partners II, L.P.

HCW

H.C. Wainwright & Co., LLC

HIPAA

Federal Health Insurance Portability and Accountability Act of 1996

ICE®

Innate cell engager

IP

Intellectual Property

Janssen

Janssen Biotech, Inc.

Kuros

Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC, collectively

Kuros RPA

the Company's Royalty Purchase Agreement with Kuros dated July 14, 2021

Medexus

Medexus Pharmaceuticals, Inc.

Merck

Merck Sharp & Dohme Corp

Merck KGaA

Ares Trading SA

Merck KGaA License Agreement

In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva IP Acquisition Agreement)

NDA

New Drug Application

NIH

National Institutes of Health

NOL

net operating loss

Novartis

Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.

November 2022 Letter Agreement

November 1, 2022 amendment to the April 2022 Letter Agreement

ObsEva

ObsEva SA

ObsEva IP Acquisition Agreement

Company's IP Acquisition Agreement with ObsEva dated November 21, 2022

Ology Bioservices

Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)

Organon

Organon International GmbH

Organon License Agreement

Out-license agreement to Organon from ObsEva dated July 26, 2021, related to the development and commercialization of ebopiprant (assumed by the Company as part of the ObsEva IP Acquisition Agreement)

Palo

Palobiofarma, S.L.

Palo RPA

the Company's Royalty Purchase Agreement with Palo dated September 26, 2019

Pfizer

Pfizer, Inc.

R&D

Research and development

Regeneron

Regeneron Pharmaceuticals, Inc.

Amended Retention Plan

October 25, 2022 amendment to the Retention Plan

2

Table of Contents

Retention Plan

Retention and Severance Plan dated March 31, 2022

Rezolute

Rezolute, Inc., formerly Antria Bio, Inc.

Rezolute License Agreement

the Company's License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019 and March 2020

RPA

Royalty Purchase Agreement

Roche

F. Hoffmann-La Roche AG

SEC

U.S. Securities and Exchange Commission

Second Bioasis RPA

the Company's Royalty Purchase Agreement with Bioasis dated November 2, 2020

Series A Preferred Stock

the 8.625% Series A cumulative, perpetual preferred stock issued in December 2020

Series B Preferred Stock

the 8.375% Series B cumulative, perpetual preferred stock issued in April 2021

Series A and Series B Preferred Stock

Series A Preferred Stock and Series B Preferred Stock, collectively

Series B Depositary Shares

the depositary shares, each representing 1/1000th interest in a share of Series B Preferred Stock

Sonnet

Sonnet BioTherapeutics, Inc., formerly Oncobiologics, Inc.

Sonnet Collaboration Agreement

the Company's Collaboration Agreement with Sonnet dated July 23, 2012, as amended in May 2019

SOX

Sarbanes-Oxley Act of 2002

SVB

Silicon Valley Bank

Takeda

Takeda Pharmaceutical Company Limited

Takeda Collaboration Agreement

the Company's Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009

TGFβ

transforming growth factor beta

VABYSMO®

faricimab-svoa

Viracta

Viracta Therapeutics, Inc.

Viracta RPA

the Company's Royalty Purchase Agreement with Viracta dated March 22, 2021

XOMA

XOMA Corporation, a Delaware corporation, including subsidiaries

3

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

XOMA CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

March 31, 

December 31, 

    

2023

    

2022

(unaudited)

(Note 1)

ASSETS

Current assets:

Cash and cash equivalents

$

44,300

$

57,826

Short-term equity securities

311

335

Trade and other receivables, net

 

6

 

1

Short-term royalty and commercial payment receivables

2,366

Prepaid expenses and other current assets

 

456

 

725

Total current assets

 

45,073

 

61,253

Property and equipment, net

 

6

 

7

Operating lease right-of-use assets

67

29

Long-term royalty and commercial payment receivables

 

73,333

 

63,683

Intangible assets, net

14,925

15,150

Other assets - long term

 

260

 

260

Total assets

$

133,664

$

140,382

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

437

$

524

Accrued and other liabilities

 

6,127

 

2,918

Contingent consideration under RPAs and CPPAs

125

75

Operating lease liabilities

69

34

Unearned revenue recognized under units-of-revenue method

 

1,968

 

1,899

Preferred stock dividend accrual

1,368

1,368

Total current liabilities

 

10,094

 

6,818

Unearned revenue recognized under units-of-revenue method – long-term

 

9,044

 

9,550

Total liabilities

 

19,138

 

16,368

Commitments and Contingencies (Note 9)

Stockholders’ equity:

Preferred Stock, $0.05 par value, 1,000,000 shares authorized:

8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at March 31, 2023 and December 31, 2022

49

49

8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at March 31, 2023 and December 31, 2022

 

Convertible preferred stock, 5,003 shares issued and outstanding at March 31, 2023 and December 31, 2022

 

 

Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,460,968 and 11,454,025 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 

86

 

86

Additional paid-in capital

 

1,306,596

 

1,306,271

Accumulated deficit

 

(1,192,205)

 

(1,182,392)

Total stockholders’ equity

 

114,526

 

124,014

Total liabilities and stockholders’ equity

$

133,664

$

140,382

The accompanying notes are an integral part of these condensed consolidated financial statements.

(Note 1) The condensed consolidated balance sheet as of December 31, 2022, has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

4

Table of Contents

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except per share amounts)

Three Months Ended

March 31, 

    

2023

    

2022

Revenues:

Revenue from contracts with customers

$

$

2,750

Revenue recognized under units-of-revenue method

 

437

 

357

Total revenues

 

437

 

3,107

Operating expenses:

 

 

Research and development

 

54

 

56

General and administrative

 

6,196

 

5,116

Arbitration settlement costs (Note 9)

 

4,132

 

Amortization of intangible assets

225

Total operating expenses

 

10,607

 

5,172

Loss from operations

 

(10,170)

 

(2,065)

Other income (expense), net:

 

 

Other income (expense), net

 

357

 

(215)

Net loss and comprehensive loss

$

(9,813)

$

(2,280)

Less: accumulated dividends on Series A and Series B preferred stock

(1,368)

(1,368)

Net loss and comprehensive loss attributable to common stockholders, basic and diluted

$

(11,181)

$

(3,648)

Basic and diluted net loss per share attributable to common stockholders

$

(0.98)

$

(0.32)

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

 

11,460

11,330

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands)

Series A 

Series B

Convertible

Additional

Total

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Paid-In

Accumulated

Stockholders’

Shares

  

Amount

  

Shares

  

Amount

  

Shares

  

Amount

     

Shares

  

Amount

 

Capital

Deficit

  

Equity

Balance, December 31, 2022

984

$

49

2

$

5

$

 

11,454

$

86

$

1,306,271

(1,182,392)

$

124,014

Issuance of common stock related to 401(k) contribution

 

 

 

 

7

 

 

123

 

 

123

Stock-based compensation expense

 

 

 

 

 

 

1,570

 

 

1,570

Preferred stock dividends

 

 

 

 

 

 

(1,368)

 

 

(1,368)

Net loss and comprehensive loss

 

 

 

 

 

 

 

(9,813)

 

(9,813)

Balance, March 31, 2023

984

$

49

2

$

5

$

 

11,461

$

86

$

1,306,596

$

(1,192,205)

$

114,526

Series A 

Series B

Convertible

Additional

Total

Preferred Stock

Preferred Stock

Preferred Stock

Common Stock

Paid-In

Accumulated

Stockholders’

Shares

  

Amount

  

Shares

  

Amount

  

Shares

  

Amount

     

Shares

  

Amount

 

Capital

Deficit

  

Equity

Balance, December 31, 2021

984

$

49

2

$

5

$

 

11,315

$

85

$

1,307,030

$

(1,165,288)

$

141,876

Exercise of stock options

 

 

 

 

91

 

1

 

632

 

 

633

Issuance of common stock related to 401(k) contribution

 

 

 

 

4

 

 

85

 

 

85

Stock-based compensation expense

 

 

 

 

 

 

978

 

 

978

Preferred stock dividends

 

 

 

 

 

 

(1,368)

 

 

(1,368)

Net loss and comprehensive loss

 

 

 

 

 

 

 

(2,280)

 

(2,280)

Balance, March 31, 2022

984

$

49

2

$

5

$

 

11,410

$

86

$

1,307,357

$

(1,167,568)

$

139,924

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Table of Contents

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

Three Months Ended March 31, 

    

2023

    

2022

Cash flows from operating activities:

Net loss

$

(9,813)

$

(2,280)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense

 

1,570

 

978

Common stock contribution to 401(k)

 

123

 

85

Amortization of intangible assets

225

Depreciation

 

1

 

2

Non-cash lease expense

 

47

 

42

Change in fair value of equity securities

 

24

 

227

Changes in assets and liabilities:

Trade and other receivables, net

 

(5)

 

184

Prepaid expenses and other assets

 

269

 

204

Accounts payable and accrued liabilities

 

3,122

 

45

Income taxes payable

(91)

Operating lease liabilities

(50)

(48)

Unearned revenue recognized under units-of-revenue method

 

(437)

 

(357)

Net cash used in operating activities

 

(4,924)

 

(1,009)

Cash flows from investing activities:

Payments of consideration under RPAs and CPPAs

(9,600)

(5,000)

Receipts under RPAs and CPPAs

2,366

Net cash used in investing activities

 

(7,234)

 

(5,000)

Cash flows from financing activities:

Payment of preferred stock dividends

(1,368)

(1,368)

Proceeds from exercise of options and other share-based compensation

 

 

1,606

Taxes paid related to net share settlement of equity awards

 

 

(973)

Net cash used in financing activities

 

(1,368)

 

(735)

Net decrease in cash, cash equivalents and restricted cash

 

(13,526)

 

(6,744)

Cash, cash equivalents and restricted cash at the beginning of the period

 

57,826

 

95,377

Cash, cash equivalents and restricted cash at the end of the period

$

44,300

$

88,633

Supplemental Cash Flow Information:

  

Cash paid for taxes

$

$

95

Right-of-use assets obtained in exchange for operating lease liabilities

$

85

$

Non-cash investing and financing activities:

 

  

  

Preferred stock dividend accrual

$

1,368

$

1,368

Estimated fair value of contingent consideration under the Aptevo CPPA

$

50

$

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Table of Contents

XOMA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business

XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company’s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company’s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs.

Liquidity and Financial Condition

The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2023, the Company had cash and cash equivalents of $44.3 million.

Based on the Company’s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 9, 2023.

These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year.

Use of Estimates

The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed

8

Table of Contents

to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Actual results may differ significantly from these estimates, such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.

Cash and Cash Equivalents

Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of March 31, 2023, the Company had a cash balance of $3.7 million and cash equivalent balances of $40.6 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2022, the Company had a cash balance of $27.5 million and cash equivalent balances of $30.3 million.

Revenue Recognition

The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.

The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.

License of intellectual property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).

9

Table of Contents

Milestone payments

At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.

If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Sale of Future Revenue Streams

The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such

10

Table of Contents

as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.

Equity Securities

The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.

The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.

Allowance for Current Expected Credit Losses

The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset’s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made.  

11

Table of Contents

Asset Acquisitions

As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4).

Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.

Cash payments related to acquired assets are reflected as an investing cash flow in the Company’s condensed consolidated statement of cash flows.

Intangible Assets

The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company’s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the condensed consolidated statement of operations and comprehensive loss.

Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.

Leases

The Company leases its headquarters office space in Emeryville, California.

The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.

Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.

12

Table of Contents

Income Taxes

The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.

The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Net Loss per Share Attributable to Common Stockholders

The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company’s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.

Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.

Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and, therefore, are not included in the diluted shares until the contingency is resolved.

Concentration of Risk

Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.

The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.

SVB was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. At the time of closing, the Company maintained approximately $4.5 million of its cash and cash equivalents in accounts with SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that depositors would have access to all of their money starting March 13, 2023. The Company had full access to the $3.7 million cash and cash equivalents held at SVB as of March 31, 2023.

The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended March 31, 2023, one

13

Table of Contents

partner represented 100% of total revenues. For the three months ended March 31, 2022, three partners represented 64%, 24% and 11% of total revenues, respectively. There was no trade receivables, net balance as of March 31, 2023 and December 31, 2022.

Comprehensive Loss

Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented.

Accounting Pronouncements Recently Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the condensed consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, Business Combinations – Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the condensed consolidated financial statements.

3. Condensed Consolidated Financial Statements Details

Equity Securities

Equity securities consisted of an investment in Rezolute’s common stock of $0.3 million for both March 31, 2023 and December 31, 2022 (Note 4). For the three months ended March 31, 2023 and 2022, the Company recognized a loss of $24,000 and $0.2 million, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss.

Intangible assets, net

The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of March 31, 2023 (in thousands):

Accumulated

Net Carrying

Cost

Amortization

Value

As of March 31, 2023

Ebopiprant IP (Note 4)

$

15,247

$

322

$

14,925

Total intangible assets

$

15,247

$

322

$

14,925

14

Table of Contents

The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands):

Accumulated

Net Carrying

Cost

Amortization

Value

As of December 31, 2022

Ebopiprant IP (Note 4)

$

15,247

$

97

$

15,150

Total intangible assets

$

15,247

$

97

$

15,150

The remaining life of the intangible assets is 16.7 years. The following table presents the projected amortization expense for the next five years (in thousands):

Intangible Asset

    

Amortization

 

2023 (excluding three months ended March 31, 2023)

$

673

2024

 

897

2025

 

897

2026

897

2027

897

Total

$

4,261

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

March 31, 

December 31, 

    

2023

    

2022

Arbitration settlement costs (Note 9)

 

4,132

 

Accrued payroll, severance and retention costs

 

1,087

 

1,449

Accrued legal and accounting fees

504

867

Accrued incentive compensation

304

562

Other accrued liabilities

100

40

Total

$

6,127

$

2,918

Net Loss Per Share Attributable to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):

Three Months Ended March 31, 

    

2023

    

2022

Numerator

 

  

 

  

Net loss

$

(9,813)

$

(2,280)

Less: Series A accumulated dividends

 

(530)

 

(530)

Less: Series B accumulated dividends

(838)

(838)

Net loss attributable to common stockholders, basic and diluted

$

(11,181)

(3,648)

 

Denominator

 

 

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

 

11,460

 

11,330

Basic and diluted net loss per share attributable to common stockholders

$

(0.98)

$

(0.32)

15

Table of Contents

Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive.

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):

Three Months Ended March 31, 

    

2023

    

2022

Convertible preferred stock

5,003

5,003

Common stock options

 

1,548

697

Warrants for common stock

 

6

6

Total

 

6,557

 

5,706

4. Licensing and Other Arrangements

ObsEva

On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva’s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva’s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones.  If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments to Merck KGaA.  The Company paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company will receive pursuant to the Organon License Agreement.

The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company’s cost to acquire said intangible asset of $15.2 million, consisting of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented 17 years. No impairment indicators were identified, and no impairment was recorded as of March 31, 2023 and December 31, 2022. The Company recognized $0.2 million of amortization expense in the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023.

The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.

As of March 31, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2023.

Novartis – Anti-TGFβ Antibody (NIS793)

On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ

16

Table of Contents

Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice.

The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015.

The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis’ obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.

In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis’ first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGFβ Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis.

In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis’ first NIS793 Phase 3 clinical trial.

The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGFβ Antibody License Agreement.

As of March 31, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2023 and 2022.

17

Table of Contents

Novartis – Anti-IL-1β Antibody (VPM087)

On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.

On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease.

Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company.

Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.

Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.

The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.

At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance

18

Table of Contents

obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of March 31, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement, and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2023 and 2022.  

Takeda

On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.

Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169 (MT-0169), and low single-digit royalties on future sales of all products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).

In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.

In November 2020, the first patient was dosed in Takeda’s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda.

In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.

No revenue was recognized for the three months ended March 31, 2023. In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $0.8 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2022.

19

Table of Contents

As of March 31, 2023 and December 31, 2022 there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement.

Rezolute

On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.

Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358.

The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute’s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.

Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 2 clinical testing. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country

The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.

No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities.

The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s financing and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock (as adjusted for the 1:50 reverse stock split in October 2020).

20

Table of Contents

In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement.

The Company recognized no revenue and $2.0 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, respectively.

As of March 31, 2023 and December 31, 2022 there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.

Janssen Biotech

The Company and Janssen were parties to a license agreement which was terminated in 2017. In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen’s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen’s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.

The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation.

The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen.

As of March 31, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2023 and 2022.  

Affimed

In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval.

The Company concluded that the commercial milestone payments are solely dependent on Affimed’s performance and achievement of specified events. The Company determined that it is not probable that a significant

21

Table of Contents

cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of March 31, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2023 and 2022.  

Sale of Future Revenue Streams

On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.

The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.

The Company recognized $0.4 million as revenue under the units-of-revenue method under these arrangements during each of the three-month periods ended March 31, 2023 and 2022. As of December 31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. As of March 31, 2023, the Company classified $2.0 million and $9.1 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.

5. Royalty and Commercial Payment Purchase Agreements

Short-term royalty and commercial payment receivables was $0 and $2.4 million as of March 31, 2023 and December 31, 2022, respectively. Long-term royalty and commercial payment receivables was $73.3 million and $63.7 million as of March 31, 2023 and December 31, 2022, respectively.

Aptevo Commercial Payment Purchase Agreement

On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between

22

Table of Contents

Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B.

Upon closing of the Aptevo CPPA, the Company paid Aptevo $9.6 million in cash, and if XOMA receives more than $0.5 million of commercial payments attributable to net sales of IXINITY that occur during the first quarter of 2023, XOMA will make a one-time payment of $50,000 to Aptevo.

At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables which includes the $9.6 million upfront payment and $50,000 one-time payment in its condensed consolidated balance sheet. The Company concluded the one-time payment of $